Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:58:33 EST Fri 13 Feb 2026
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q0.1155.49·155.600.1155.55+3.742.52,000.2307,38418,833151.89  155.95  151.46157.27  93.3711:38:02Feb 1015 min RT 2¢

Recent Trades - Last 10 of 18833
Time ETExPriceChangeVolume
11:38:11Q155.5353.725256
11:38:11Q155.503.6920
11:38:11Q155.493.681
11:38:11Q155.493.683
11:38:11Q155.493.68100
11:38:11Q155.493.683
11:38:11Q155.493.684
11:38:11Q155.493.685
11:38:11Q155.493.681
11:38:11Q155.493.6820

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-10 16:02U:GILDNews ReleaseGilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
2026-02-10 16:01U:GILDNews ReleaseGilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
2026-02-06 08:30U:GILDNews ReleaseFDA Approves Label Update for Kite's Yescarta(TM) for Relapsed/Refractory Primary Central Nervous System Lymphoma
2026-01-27 16:05U:GILDNews ReleaseGilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
2026-01-21 17:00U:GILDNews ReleaseNew England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy(TM) Plus Keytruda(TM) as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
2025-12-22 16:05U:GILDNews ReleaseGilead Sciences to Present at Upcoming Investor Conference
2025-12-22 08:00U:GILDNews ReleaseGilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
2025-12-19 14:21U:GILDNews ReleaseGilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
2025-12-18 08:30U:GILDNews ReleaseGilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
2025-12-15 08:30U:GILDNews ReleaseGilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
2025-12-12 10:31U:GILDNews ReleaseGI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
2025-12-09 08:30U:GILDNews ReleaseGilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
2025-12-07 08:00U:GILDNews ReleaseYescarta(TM) Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
2025-12-06 14:00U:GILDNews ReleaseKite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma
2025-12-06 14:00U:GILDNews ReleaseKite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
2025-11-24 08:30U:GILDNews ReleaseGilead Foundation Commits Over $3 Million to Address Food Insecurity
2025-11-20 07:02U:GILDNews ReleaseAspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
2025-11-18 05:00U:GILDNews ReleaseGilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
2025-11-13 08:30U:GILDNews ReleaseGilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
2025-11-07 08:30U:GILDNews ReleaseGilead Provides Update on Phase 3 ASCENT-07 Study